CD22 and neoplasm: The team of Hong S also reported a chemoenzymatic glycocalyx editing strategy to introduce high-affinity and specific CD22 ligands onto NK-92MI and cytokine-induced NK cells to achieve tumor-specific CD22 targeting (112).